---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-033265"
form_type: "8-K"
ticker: "EVFM"
cik: "0001618835"
company_name: "Evofem Biosciences, Inc."
filed_at: "2024-08-20T23:59:59+00:00"
generated_at: "2026-05-31T08:28:27.521163+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Evofem and Aditxt amend merger, extend third equity investment deadline contingent on Aditxt raising $20M

## Summary
- Third Parent Equity Investment deadline moved to earlier of Sep 6, 2024 or 5 business days after Aditxt closes a ≥$20M public offering.
- Aditxt must purchase 2,000 shares of Evofem Series F-1 Preferred for $2,000,000 on that date.
- Other investment dates unchanged: $500k (Jul 12), $500k (Aug 9), $1,000k (Sep 30).
- Amendment signed Aug 16, 2024 by CEOs of Evofem (Saundra Pelletier) and Aditxt (Amro Albanna).

## SEC filing metadata
- accession: 0001493152-24-033265
- form_type: 8-K
- ticker: EVFM
- cik: 0001618835
- company_name: Evofem Biosciences, Inc.
- filed_at: 2024-08-20T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1618835/000149315224033265/0001493152-24-033265-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1618835/000149315224033265/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-033265
- JSON: https://secwatch.observer/filing/0001493152-24-033265.json
- Plain text: https://secwatch.observer/filing/0001493152-24-033265.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.